Singapore markets closed

Xbrane Biopharma AB (7XB.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.0220+0.0036 (+19.57%)
As of 02:13PM CEST. Market open.
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
238,800
238,800
57,700
10,709
7,092
Cost of revenue
203,341
203,341
0
0
0
Gross profit
35,388
35,388
57,618
10,709
7,092
Operating expenses
Research development
305,783
305,783
199,648
160,619
197,284
Selling general and administrative
40,031
40,031
31,538
31,395
26,505
Total operating expenses
345,344
345,344
231,186
187,166
223,738
Operating income or loss
-309,956
-309,956
-173,568
-176,457
-216,646
Interest expense
18,501
18,501
2,583
2,636
691
Income before tax
-322,028
-322,028
-168,513
-183,226
-218,126
Income tax expense
0
0
0
0
0
Income from continuing operations
-322,028
-322,028
-168,513
-183,226
-218,126
Net income
-388,172
-388,172
-172,513
-188,376
-226,026
Net income available to common shareholders
-388,172
-388,172
-172,513
-188,376
-226,026
Basic EPS
-1.18
-1.53
-0.77
-0.90
-1.41
Diluted EPS
-1.18
-1.53
-0.77
-0.90
-1.41
Basic average shares
246,926
253,210
225,551
208,115
159,776
Diluted average shares
246,926
253,210
225,551
208,115
159,776